Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw unusually-high trading volume on Tuesday . Approximately 13,175 shares traded hands during trading, a decline of 53% from the previous session’s volume of 28,180 shares.The stock last traded at $8.31 and had previously closed at $8.10.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research report on Friday.

Aligos Therapeutics Trading Down 1.2 %

The firm’s fifty day moving average price is $13.09 and its 200 day moving average price is $16.08. The firm has a market capitalization of $624.88 million, a PE ratio of -6.33 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The business had revenue of $1.06 million for the quarter. During the same quarter in the prior year, the firm earned ($10.75) earnings per share. As a group, research analysts expect that Aligos Therapeutics, Inc. will post -8.15 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC boosted its holdings in Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares in the last quarter. Opaleye Management Inc. boosted its holdings in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares in the last quarter. Finally, Altitude Crest Partners Inc. bought a new stake in Aligos Therapeutics in the fourth quarter worth $1,889,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).